Thyroid Cancer pp 165-180 | Cite as

Follow-up of Patients with Well-Differentiated Thyroid Cancer

  • B. Shapiro
  • M. D. Gross


Thyroid cancer appears to receive a significant amount of attention in the medical literature that is out of proportion to its incidence. Whether this interest is the result of its demographics — thyroid cancer tends to affect both old and young, with a slight female predominance — or because thyroid cancer is linked to prior radiation exposure remains a mystery [33, 39]. The recent spate of cases of thyroid cancer in children in Belarus and Ukraine as a result of the Chernobyl disaster has certainly sparked considerable interest in its etiology and genetics [46]. Despite the considerable interest in this rare neoplasm, however, there are no universally accepted algorithms for either initial therapy or follow-up care for thyroid cancer. Controversies continue with respect to almost every aspect of the management of the thyroid cancer patient (Table 11.1). We will outline our approach to the thyroid cancer patient that has evolved at the University of Michigan over the last 4 decades.


Thyroid Hormone Thyroid Cancer Thyroid Carcinoma Papillary Thyroid Carcinoma Papillary Thyroid Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ball DW (2000) Medullary thyroid carcinoma. In: Wartofsky L (ed) Thyroid cancer. A comprehensive guide to clinical management. Humana Press, Totowa, N.J., pp 365–381Google Scholar
  2. 2.
    Baudin E, Schlumberger M, Lumbrosa J. et al. (1996) Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scans. J Clin Endocrinol Metab 81: 2451–2544CrossRefGoogle Scholar
  3. 3.
    Beierwaltes WH, Rabbini R, Dmuchowski C, Lloyd RV, Eyre P, Mallette S (1984) An analysis of “ablation of thyroid remnants” with 131I in 511 patients from 1947–1984. J Nucl Med 25: 1287–1293PubMedGoogle Scholar
  4. 4.
    Benua RS, Cicale NR, Sonenberg M (1962) The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. AJR 87: 171–182Google Scholar
  5. 5.
    Brendel AJ, Guyot M, Jeandot R, Lefolt G, Manicet G (1998) Thallium-201 imaging in the follow-up of differentiated thyroid carcinoma. J Nucl Med 29: 1515–1520Google Scholar
  6. 6.
    Burch HB (2000) Papillary thyroid cancer. Follow up. In: Wartofsky L (ed) Thyroid cancer. A comprehensive guide to clinical management. Humana Press, Totowa, N.J., pp 229–237Google Scholar
  7. 7.
    Burman KD (1995) How serious are the risks of thyroid hormone over-replacement? Thyroid Today 18: 1–9Google Scholar
  8. 8.
    Burmeister LA, Goumaz MO, Mariassh CN, Oppenheimer JH (1992) Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid Cancer. J Clin Endocrinol Metab 75: 344–350PubMedCrossRefGoogle Scholar
  9. 9.
    Clark OH, Duh QY (1990) Thyroid cancer. In: Green MA (ed) The thyroid gland. Raven Press, New York, pp 537–572Google Scholar
  10. 10.
    Clark OH, Elmhed J (1995) Thyroid surgery-past, present and future. Thyroid Today 38: 1–9Google Scholar
  11. 11.
    Clarke SEM (1991) Radioiodine therapy of the thyroid. In: Murray IPC, Ell PJ (eds) Nuclear medicine in clinical diagnosis and therapy. Churchill and Livingstone, Edinburgh, pp 1049–1062Google Scholar
  12. 12.
    Clarke SEM, Lazarus CR, Edwards S, et al. (1987) Scintigraphy and treatment of medullary carcinoma of the thyroid with iodine-131 mataiodobenzylguanidine. J Nucl Med 28: 1820–1825PubMedGoogle Scholar
  13. 13.
    Clarke SEM, Lazarus CR, Wraight P, Sampson C, Maisey MN (1988) Pentavalent [99m-Tc] DMSA, [131-I] MIBG, and [99m-Tc] MDP: an evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid. J Nucl Med 29: 33–38PubMedGoogle Scholar
  14. 14.
    Dadparvars S, Chevres A, Tulchinsky M, Krishna-Badrinath L, Khan AS, Slizofski WJ (1995) Clinical utility of technetium-99m methoxyisobutylisonitrite imaging in differentiated thyroid carcinoma: comparison with thallium-201 and iodine-131 Na scintigraphy and thyroglobulin quantitation. Eur J Nucl Med 22: 1330–1338CrossRefGoogle Scholar
  15. 15.
    DeGroot LJ, Kaplan EL, McCormick M, Straus FH (1990) Natural history, treatment and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 71: 414–424PubMedCrossRefGoogle Scholar
  16. 16.
    Eng C, Clayton D, Schuffenecker I, et al. (1996) The relationship between specific RET protoncogene mutations and diseased phenotype in multiple endocrine neoplasia type 2: international RET mutation consortium analysis. JAMA 276: 1575–1579PubMedCrossRefGoogle Scholar
  17. 17.
    Fatourechi V, Hay ID (2000) Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases: including comments on the role of serum thyroglobulin monitoring in tumor surveillance. Semin Nucl Med 30: 107–114.PubMedCrossRefGoogle Scholar
  18. 18.
    Feine V, Lietzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schauenberg W (1996) Fluorine-18-FDG and iodine-131-iodine uptake in thyroid cancer. J Nucl Med 37: 1468–1472PubMedGoogle Scholar
  19. 19.
    Freitas JE, Gross MD, Ripley SD, Shapiro B (1986) Radionuclide diagnosis and therapy of thyroid cancer: current status report. In: Freeman LM (ed) Freeman and Johnson’s clinical radionuclide imaging. Grune and Stratton, Orlando, Fl., pp 1994–2027Google Scholar
  20. 20.
    Goldman JM, Line BR, Aamodt RL, et al. (1980) Influence of triiodothyronine withdrawal time on 131-I uptake post-thyroidectomy for thyroid cancer. J Endocrinol Metab 50: 734–739CrossRefGoogle Scholar
  21. 21.
    Harness JK, Fund L, Thompson NW, Burney RE, McLeod MK (1986) Total thyroidectomy: complications and technique. World J Surg 10: 781–786PubMedCrossRefGoogle Scholar
  22. 22.
    Hay ID (1989) Prognostic factors in thyroid carcinoma. Thyroid Today 12: 1–9Google Scholar
  23. 23.
    Hurley RJ, Becker DV (1983) The use of radioiodine in the management of thyroid cancer. In: Freeman LM, Weissman HS (eds) Nuclear medicine annual 1983. Raven Press, New York, pp 348–349Google Scholar
  24. 24.
    Jeevanram RK, Shah DH, Sharma SM, Ganatra RD (1986) Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients. Nucl Med Biol 13: 277–279Google Scholar
  25. 25.
    Johnston G, Sweeney D (2000) Radioiodine therapy of thyroid cancer. General considerations–I. In: Wartofsky L (ed) Thyroid cancer. A comprehensive guide to clinical management. Humana Press, Totowa, N.J., pp 147–153Google Scholar
  26. 26.
    Kosuda S, Yokoyama H, Katayama M, Yokokawa T, Kusano S, Yamamoto O (1995) Technetium-99m tetrofosmin and technetium-99m sestamibi imaging of multiple metastases from differentiated thyroid carcinoma. Eur J Nucl Med 22: 1218–1220PubMedCrossRefGoogle Scholar
  27. 27.
    Kwekkeboom DJ, Reubi JC, Lamberts SWJ, et al. (1993) In vivo somatostatin-receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 76: 1413–1417PubMedCrossRefGoogle Scholar
  28. 28.
    Ladenson PW (2000) Recombinant thyrotropin versus thyroid hormone withdrawal in evaluating patients with thyroid carcinoma. Semin Nucl Med 30: 98–106PubMedCrossRefGoogle Scholar
  29. 29.
    Lennquist S (1986) Surgical strategy in thyroid carcinoma; a clinical review. Acta Chir Scand 152: 321–338.PubMedGoogle Scholar
  30. 30.
    Massin JP, Savoie JC, Gamier H, Guiaraudon G, Leger FA, Bacourt P (1984) Pulmonary metastases in differentiated thyroid carcinoma,. Study of 58 cases with implications for the primary tumor treatment. Cancer 53: 982–992PubMedCrossRefGoogle Scholar
  31. 31.
    Maxon HR, Smith HS (1990) Radioiodine-131 in the diagnosis and treatment of well differentiated thyroid cancer. Endocrinol Metab Clin North Am 19: 685–718PubMedGoogle Scholar
  32. 32.
    Mazzaferri EL (1991) Treating differentiated thyroid carcinoma: where do we draw the line? Mayo Clin Proc 66: 105–111PubMedCrossRefGoogle Scholar
  33. 33.
    Mazzaferri E (1995) Impact of initial tumor features and treatment selected on the long term course of differentiated thyroid cancer. Thyroid Today 28: 1–13Google Scholar
  34. 34.
    Nygaards BJ, Hegedus L, Gervil M, Hjalgrim H, Soe-Jensen P, Hansen JM (1993) Radioiodine treatment of multinodular goiter. Br Med J 307: 828–832CrossRefGoogle Scholar
  35. 35.
    O’Byrne KJ, Hamilton D, Robinson I, Sweeney E, Freyne PG, Cullen MJ (1992) Imaging of medullary carcinoma of the thyroid using 111-In labeled anti-CEA monoclonal antibody fragments. Nucl Med Commun 13: 142–148PubMedCrossRefGoogle Scholar
  36. 36.
    Ozata M, Suzuki S, Miyamoto T, Liu RT, Fierro-Renoy F, DeGroot LJ (1994) Serum thyrotropin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 79: 98–105PubMedCrossRefGoogle Scholar
  37. 37.
    Park H (1992) Stunned thyroid after high-dose I-131 imaging. Clin Nucl Med 17: 501–502PubMedCrossRefGoogle Scholar
  38. 38.
    Riccabona G (1991) Differentiated thyroid carcinoma. In: Murray IPC, Ell PJ (eds) Nuclear medicine in clinical diagnosis and therapy. Churchill and Livingstone, Edinburgh, pp 941–957Google Scholar
  39. 39.
    Ron E, Lubin JH, Shore RE, et al. (1995) Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 141: 259–277PubMedCrossRefGoogle Scholar
  40. 40.
    Samaan NA, Maheshwari YK, Nader S, et al. (1983) Impact of therapy for differentiated carcinoma of the thyroid: an analysis of 706 cases. J Endocrinol Metab 56: 1131–1138CrossRefGoogle Scholar
  41. 41.
    Samaan NA, Schultz PN. Hickey RC, Haynie TP, Johnston DA, Ordonez NG (1992) Well-differentiated thyroid carcinoma and the results of various modalities of treatment. A retrospective review of 1599 patients. J Clin Endocrinol Metab 75: 714–720PubMedCrossRefGoogle Scholar
  42. 42.
    Shapiro B, Ruffini V, Jarwan A, et al. (2000) Artifacts, anatomical and physiological variants, and unrelated diseases that might cause false-positive whole body scans in patients with thyroid cancer. Semin Nucl Med 30: 115–132PubMedCrossRefGoogle Scholar
  43. 43.
    Sisson JC (1989) Medical treatment of benign and malignant thyroid tumors. Endocrinol Metab Clin North Am 18: 359–387PubMedGoogle Scholar
  44. 44.
    Sweeney D, Johnston G (2000) Radioiodine treatment of thyroid cancer. IL Maximizing therapeutic and diagnostic l31í uptake. In: Wartofsky L (ed) Thyroid cancer. A comprehensive guide to clinical management. Humana Press, Totowa, N.J., pp 239–250Google Scholar
  45. 45.
    Tallroth E, Lundell G, Tennvall J, Wallin G (1990) Chemotherapy and multimodality treatment in thyroid carcinoma: disorders of the thyroid and parathyroid II. Otolaryngol Clin North Am 32: 523–527Google Scholar
  46. 46.
    Tuttle RM, Becker DV (2000) The Chernobyl accident and its consequences: update at the Millennium. Semin Nucl Med 30: 133–140.PubMedCrossRefGoogle Scholar
  47. 47.
    Van de Velde CJH, Hamming JF, Goslings BM, Schelfhout LJDM, Clark OH, Smeds S, et al. (1988) Report of the Consensus Development Conference on the Management of Differentiated Thyroid Cancer in The Netherlands. Eur J Cancer Clin Oncol 24: 287–292CrossRefGoogle Scholar
  48. 48.
    Wartofsky L (2000) An approach to the management of patients with scan negative, thyroglobulin positive, differentiated thyroid carcinoma. In: Wartofsky L (ed) Thyroid cancer. A comprehensive guide to clinical management. Humana Press, Totowa, N.J., pp 251–261Google Scholar
  49. 49.
    White RL (2000) Management of papillary thyroid carcinoma. In: Wartofsky L (ed) Thyroid cancer. A comprehensive guide to clinical management. Humana Press, Totowa, N.J., pp 225–228Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • B. Shapiro
  • M. D. Gross

There are no affiliations available

Personalised recommendations